Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Developmental Milestones in Pediatric Research; A Case for Including Efficacy as Part of Interventional Trials in Infants with Cystic Fibrosis.

Sanders DB, Nichols DP.

Am J Respir Crit Care Med. 2018 Nov 13. doi: 10.1164/rccm.201811-2103ED. [Epub ahead of print] No abstract available.

PMID:
30422678
2.

A population of luminous accreting black holes with hidden mergers.

Koss MJ, Blecha L, Bernhard P, Hung CL, Lu JR, Trakthenbrot B, Treister E, Weigel A, Sartori LF, Mushotzky R, Schawinski K, Ricci C, Veilleux S, Sanders DB.

Nature. 2018 Nov;563(7730):214-216. doi: 10.1038/s41586-018-0652-7. Epub 2018 Nov 7.

PMID:
30405225
3.

Quantitative chest computerized tomography and FEV1 equally identify pulmonary exacerbation risk in children with cystic fibrosis.

Sanders DB, Li Z, Parker-McGill K, Farrell P, Brody AS.

Pediatr Pulmonol. 2018 Oct;53(10):1369-1377. doi: 10.1002/ppul.24144. Epub 2018 Aug 29.

PMID:
30160050
4.

Reply.

Nandedkar SD, Sanders DB, Hobson-Webb LD, Billlakota S, Barkhaus PE, Stalberg EV.

Muscle Nerve. 2018 Oct;58(4):E31-E32. doi: 10.1002/mus.26198. Epub 2018 Sep 18. No abstract available.

PMID:
30043996
5.

Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Hewett K, Sanders DB, Grove RA, Broderick CL, Rudo TJ, Bassiri A, Zvartau-Hind M, Bril V; BEL115123 Study Group.

Neurology. 2018 Apr 17;90(16):e1425-e1434. doi: 10.1212/WNL.0000000000005323. Epub 2018 Mar 21.

6.

Problems in Comparing Jitter Values Obtained with Voluntary Activation and Electrical Stimulation.

Stålberg E, Kouyoumdjian JA, Paiva GP, Yanaze LL, Sanders DB.

J Neuromuscul Dis. 2018;5(2):225-230. doi: 10.3233/JND-170289.

PMID:
29614693
7.

Reply.

Sanders DB, Harati Y, Juel VC, Lou JS, Marburger T, Pascuzzi RM, Peltier AC, Richman DP, Smith AG.

Muscle Nerve. 2018 May;57(5):E130-E131. doi: 10.1002/mus.26089. Epub 2018 Mar 1. No abstract available.

PMID:
29406616
8.

Early life growth patterns persist for 12 years and impact pulmonary outcomes in cystic fibrosis.

Sanders DB, Zhang Z, Farrell PM, Lai HJ; Wisconsin CF Neonatal Screening Group.

J Cyst Fibros. 2018 Jul;17(4):528-535. doi: 10.1016/j.jcf.2018.01.006. Epub 2018 Feb 1.

PMID:
29396025
9.

Developing treatment guidelines for myasthenia gravis.

Sanders DB, Wolfe GI, Narayanaswami P; MGFA Task Force on MG Treatment Guidance.

Ann N Y Acad Sci. 2018 Jan;1412(1):95-101. doi: 10.1111/nyas.13537. Review.

PMID:
29381223
10.

Comparative effectiveness clinical trials to advance treatment of myasthenia gravis.

Guptill JT, Raja S, Sanders DB, Narayanaswami P.

Ann N Y Acad Sci. 2018 Feb;1413(1):69-75. doi: 10.1111/nyas.13582. Epub 2018 Jan 28. Review.

PMID:
29377158
11.

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP; Dapper Study Team.

Muscle Nerve. 2018 Apr;57(4):561-568. doi: 10.1002/mus.26052. Epub 2018 Feb 2.

12.

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Heltshe SL, West NE, VanDevanter DR, Sanders DB, Beckett VV, Flume PA, Goss CH; STOP Study Group.

Contemp Clin Trials. 2018 Jan;64:35-40. doi: 10.1016/j.cct.2017.11.012. Epub 2017 Nov 21.

PMID:
29170074
13.

Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Heltshe SL, Khan U, Beckett V, Baines A, Emerson J, Sanders DB, Gibson RL, Morgan W, Rosenfeld M.

J Cyst Fibros. 2018 May;17(3):341-347. doi: 10.1016/j.jcf.2017.10.008. Epub 2017 Oct 28.

PMID:
29110966
14.

Pitfalls and errors in measuring jitter.

Stålberg E, Sanders DB, Kouyoumdjian JA.

Clin Neurophysiol. 2017 Nov;128(11):2233-2241. doi: 10.1016/j.clinph.2017.09.001. Epub 2017 Sep 21. Review.

PMID:
29017138
15.

Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.

Sanders DB, Zhao Q, Li Z, Farrell PM.

Pediatr Pulmonol. 2017 Oct;52(10):1268-1275. doi: 10.1002/ppul.23765. Epub 2017 Sep 7.

16.

Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV1 decline.

Sanders DB, Li Z, Zhao Q, Farrell PM.

J Cyst Fibros. 2017 Jul 29. pii: S1569-1993(17)30818-4. doi: 10.1016/j.jcf.2017.07.003. [Epub ahead of print]

PMID:
28765072
17.

Reliability of the triple-timed up-and-go test.

Sanders DB, Guptill JT, Aleš KL, Hobson-Webb LD, Jacobus DP, Mahmood R, Massey JM, Pittman MM, Prather K, Raja SM, Yow E, Juel VC.

Muscle Nerve. 2018 Jan;57(1):136-139. doi: 10.1002/mus.25700. Epub 2017 Jun 6.

PMID:
28545168
18.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

19.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

PMID:
28457954
20.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

VanDevanter DR, Heltshe SL, Spahr J, Beckett VV, Daines CL, Dasenbrook EC, Gibson RL, Raksha J, Sanders DB, Goss CH, Flume PA; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):607-615. doi: 10.1016/j.jcf.2017.04.004. Epub 2017 Apr 21.

PMID:
28438499
21.

Marked clinical and jitter improvement after eculizumab in refractory myasthenia.

Juel VC, Sanders DB, Hobson-Webb LD, Massey JM, Guptill JT, O'Brien F, Wang JJ, Howard JF Jr.

Muscle Nerve. 2017 Sep;56(3):E16-E18. doi: 10.1002/mus.25620. Epub 2017 Jun 5. No abstract available.

PMID:
28214342
22.

The extrapolated reference values procedure: Theory, algorithm, and results in patients and control subjects.

Nandedkar SD, Sanders DB, Hobson-Webb LD, Billakota S, Barkhaus PE, Stålberg EV.

Muscle Nerve. 2018 Jan;57(1):90-95. doi: 10.1002/mus.25606. Epub 2017 Apr 10.

PMID:
28181271
23.

Author response: International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Narayanaswami P.

Neurology. 2017 Jan 31;88(5):505-506. doi: 10.1212/WNL.0000000000003570. No abstract available.

PMID:
28138082
24.

Diagnosis of Cystic Fibrosis in Screened Populations.

Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA.

J Pediatr. 2017 Feb;181S:S33-S44.e2. doi: 10.1016/j.jpeds.2016.09.065.

25.

Does change in neuromuscular jitter predict or correlate with clinical change in MG?

Sanders DB, Massey JM.

Muscle Nerve. 2017 Jul;56(1):45-50. doi: 10.1002/mus.25440. Epub 2017 Feb 15.

PMID:
27759891
26.

Background and Epidemiology.

Sanders DB, Fink AK.

Pediatr Clin North Am. 2016 Aug;63(4):567-84. doi: 10.1016/j.pcl.2016.04.001. Review.

27.

International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P.

Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Review.

28.

Factors affecting outcome in myasthenia gravis.

Andersen JB, Gilhus NE, Sanders DB.

Muscle Nerve. 2016 Dec;54(6):1041-1049. doi: 10.1002/mus.25205.

PMID:
27251303
29.

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r.

Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M.

Muscle Nerve. 2016 Dec;54(6):1015-1022. doi: 10.1002/mus.25198. Epub 2016 Nov 7.

PMID:
27220659
30.

Lambert-Eaton myasthenia?

Sanders DB.

Muscle Nerve. 2016 Mar;53(3):495. doi: 10.1002/mus.25001. Epub 2016 Jan 23. No abstract available.

PMID:
26661270
31.

ATS Core Curriculum 2015: Part III. Pediatric Pulmonary Medicine.

Boyer D, Nevin M, Thomson CC, Sanders DB, Alexiou S, Goldfarb SB, Nicholas JL, Thacker PG, Coverstone AM, Faro A, Cheng G, Majid A, Moore PE.

Ann Am Thorac Soc. 2015 Nov;12(11):1688-96. doi: 10.1513/AnnalsATS.201506-322CME. No abstract available.

32.

The epidemiology of poor outcomes after pulmonary exacerbations.

Sanders DB.

J Cyst Fibros. 2015 Nov;14(6):679-80. doi: 10.1016/j.jcf.2015.10.002. Epub 2015 Oct 21. No abstract available.

33.

Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years.

Sanders DB, Fink A, Mayer-Hamblett N, Schechter MS, Sawicki GS, Rosenfeld M, Flume PA, Morgan WJ.

J Pediatr. 2015 Nov;167(5):1081-8.e1. doi: 10.1016/j.jpeds.2015.07.044. Epub 2015 Sep 2.

34.

Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis.

Sanders DB, Emerson J, Ren CL, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Ann Am Thorac Soc. 2015 Aug;12(8):1170-6. doi: 10.1513/AnnalsATS.201504-198OC.

35.

Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.

Benatar M, Mcdermott MP, Sanders DB, Wolfe GI, Barohn RJ, Nowak RJ, Hehir M, Juel V, Katzberg H, Tawil R; Muscle Study Group (MSG).

Muscle Nerve. 2016 Mar;53(3):363-9. doi: 10.1002/mus.24769. Epub 2016 Jan 27.

36.

Reference values for jitter recorded by concentric needle electrodes in healthy controls: A multicenter study.

Stålberg E, Sanders DB, Ali S, Cooray G, Leonardis L, Löseth S, Machado F, Maldonado A, Martinez-Aparicio C, Sandberg A, Smith B, Widenfalk J, Aris Kouyoumdjian J.

Muscle Nerve. 2016 Mar;53(3):351-62. doi: 10.1002/mus.24750. Epub 2015 Nov 13.

PMID:
26112058
37.

Stimulated jitter in infant botulism.

Sanders DB.

Muscle Nerve. 2015 Oct;52(4):691-2. doi: 10.1002/mus.24737. Epub 2015 Jul 1. No abstract available.

PMID:
26096260
38.

Risk factors for lung function decline in a large cohort of young cystic fibrosis patients.

Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group.

Pediatr Pulmonol. 2015 Aug;50(8):763-70. doi: 10.1002/ppul.23217. Epub 2015 Jun 9.

39.

Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening.

Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, Rosenfeld M, Marshall BC.

Pediatrics. 2015 Jun;135(6):e1386-92. doi: 10.1542/peds.2014-3698. Epub 2015 May 11.

40.

Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA.

Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.

41.

Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.

Guptill JT, Yi JS, Sanders DB, Guidon AC, Juel VC, Massey JM, Howard JF Jr, Scuderi F, Bartoccioni E, Evoli A, Weinhold KJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Feb 26;2(2):e77. doi: 10.1212/NXI.0000000000000077. eCollection 2015 Apr.

42.

A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis.

Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI; Tirasemtiv in Myasthenia Gravis Study Group.

Neurotherapeutics. 2015 Apr;12(2):455-60. doi: 10.1007/s13311-015-0345-y.

43.

Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States.

Burns TM, Sanders DB, Kaminski HJ, Wolfe GI, Narayanaswami P, Venitz J.

Muscle Nerve. 2015 May;51(5):635-7. doi: 10.1002/mus.24608. Epub 2015 Mar 31. No abstract available.

PMID:
25704880
44.

A genome-wide association study of myasthenia gravis.

Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chiò A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF Jr, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ.

JAMA Neurol. 2015 Apr;72(4):396-404. doi: 10.1001/jamaneurol.2014.4103.

45.

Chest computed tomography predicts the frequency of pulmonary exacerbations in children with cystic fibrosis.

Sanders DB, Li Z, Brody AS.

Ann Am Thorac Soc. 2015 Jan;12(1):64-9. doi: 10.1513/AnnalsATS.201407-338OC.

46.

Myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Sanders DB, Guptill JT.

Continuum (Minneap Minn). 2014 Oct;20(5 Peripheral Nervous System Disorders):1413-25. doi: 10.1212/01.CON.0000455873.30438.9b. Review.

PMID:
25299290
47.

Phenotypes that matter: Pseudomonas aeruginosa and progression of cystic fibrosis lung disease.

Sanders DB.

Am J Respir Crit Care Med. 2014 Aug 1;190(3):245-6. doi: 10.1164/rccm.201406-1145ED. No abstract available.

PMID:
25084257
48.

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.

Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, Krueger A, Sanders DB.

Muscle Nerve. 2014 Jul;50(1):47-51. doi: 10.1002/mus.24109. Epub 2014 May 2.

PMID:
24639235
49.

Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Yi JS, Guidon A, Sparks S, Osborne R, Juel VC, Massey JM, Sanders DB, Weinhold KJ, Guptill JT.

J Autoimmun. 2014 Aug;52:130-8. doi: 10.1016/j.jaut.2013.12.005. Epub 2013 Dec 28.

50.

Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis?

Sanders DB, Cao L, Massey JM, Juel VC, Hobson-Webb L, Guptill JT.

Clin Neurophysiol. 2014 Jun;125(6):1274-7. doi: 10.1016/j.clinph.2013.11.007. Epub 2013 Nov 16.

PMID:
24332471

Supplemental Content

Loading ...
Support Center